← Back to Search

RAS Inhibitor

RMC-6236 for Pancreatic Cancer (RASolute 302 Trial)

Fairfax, VA
Phase 3
Recruiting
Research Sponsored by Revolution Medicines, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically or cytologically confirmed PDAC with metastatic disease
Documented RAS mutation status, either mutant or wild-type. Eligible RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Must not have
Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors)
Patient is unable or unwilling to comply with protocol-required study visits or procedures
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 3 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

"This trial aims to test a new drug to see if it is safe and effective in treating a certain condition, comparing it to the current standard treatments."

See full description
Who is the study for?
This trial is for patients with advanced pancreatic cancer (PDAC) who have already undergone treatment. Participants should be adults with a confirmed diagnosis and measurable disease, able to perform daily activities with relative independence.Check my eligibility
What is being tested?
The study tests RMC-6236, a new potential drug targeting specific cancer pathways, against standard chemotherapy treatments like 5-fluorouracil, irinotecan, nab-paclitaxel, gemcitabine, oxaliplatin and liposomal irinotecan combined with leucovorin.See study design
What are the potential side effects?
Potential side effects may include typical chemotherapy-related issues such as nausea, vomiting, diarrhea or constipation; fatigue; hair loss; lowered blood cell counts leading to increased infection risk; and possible liver toxicity.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My pancreatic cancer has spread and was confirmed by lab tests.
 show original
Select...
My cancer has a known RAS mutation status.
 show original
Select...
I am fully active or can carry out light work.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been treated with drugs targeting RAS proteins.
 show original
Select...
I cannot or do not want to follow the study's required visits or procedures.
 show original
Select...
I have or had cancer spread to my brain or spinal cord.
 show original
Select...
I have not had major surgery in the last 4 weeks.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall survival (OS) in the RAS G12-mutant population
Progression free survival (PFS) in the RAS G12-mutant population
Secondary study objectives
Duration of response (DOR) in RAS G12 and all-patient populations
OS in the all-patient population
Objective response in the RAS G12 and all-patient populations
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: RMC-6236Experimental Treatment1 Intervention
Study drug
Group II: Investigator's choice of standard of care therapyActive Control7 Interventions
Patients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments: * Gemcitabine and nab-paclitaxel (GnP) * Oxaliplatin, leucovorin, irinotecan, and 5-FU (Modified FOLFIRINOX: mFOLFIRINOX) * Liposomal irinotecan (Nal-IRI + 5-FU/LV) * Oxaliplatin, leucovorin and 5-FU IV (FOLFOX)

Find a Location

Closest Location:Virginia Cancer Specialists· Fairfax, VA

Who is running the clinical trial?

Revolution Medicines, Inc.Lead Sponsor
12 Previous Clinical Trials
3,618 Total Patients Enrolled
Study DirectorStudy DirectorRevolution Medicines
1,305 Previous Clinical Trials
500,662 Total Patients Enrolled
~307 spots leftby Jun 2026